AJANTA PHARMA Quarterly Results - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA Quarterly Results    (AJPH)

Here are the latest quarterly results of AJANTA PHARMA. For more details, see the AJANTA PHARMA financial fact sheet and AJANTA PHARMA share price and chart. For a sector overview, read our pharmaceuticals sector report.

Excel Export | Annual Financial Info | Result Scoreboard

AJANTA PHARMA Quarterly Results

No. of Mths
Qtr. Ending
3
Dec-18
*
3
Mar-19
*
3
Jun-19
*
3
Sep-19
*
3
Dec-19
*
3
Mar-20
*
3
Jun-20
*
3
Sep-20
*
8-Qtr Chart
Click to enlarge
Net Sales Rs m4,8515,1526,1196,4286,5126,8206,6827,159 
Other income Rs m44167613214656713149 
Turnover Rs m4,8955,1686,1966,5606,6597,3876,8137,208 
Expenses Rs m3,7783,8814,4364,6514,6525,3064,4504,417 
Gross profit Rs m1,0731,2711,6841,7661,8561,4882,2322,743 
Depreciation Rs m187188228233236260280283 
Interest Rs m18184916361615 
Profit before tax Rs m9301,0921,5151,6161,7511,7592,0672,492 
Tax Rs m261203368452676467589790 
Profit after tax Rs m6698891,1461,1641,0761,2921,4781,702 
Gross profit margin %22.124.727.527.528.521.833.438.3 
Effective tax rate %28.018.624.328.038.626.628.531.7 
Net profit margin %13.817.318.718.116.518.922.123.8 
Diluted EPS Rs 7.6 10.1 13.0 13.2 12.2 14.7 16.8 19.4  
Diluted EPS (TTM) Rs 44.6 44.0 45.0 44.0 48.6 53.2 56.9 63.1  
 Subscriber Feature                  
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Read: AJANTA PHARMA 2QFY21 Result Performance Review

More Pharmaceuticals Company Quarterly Results:   INDRAPRASTHA MEDICAL  FULFORD INDIA  BIOCON   NEULAND LABS  GLENMARK PHARMA  

Compare AJANTA PHARMA With:   INDRAPRASTHA MEDICAL  FULFORD INDIA  BIOCON   NEULAND LABS  GLENMARK PHARMA  

Compare AJANTA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

5 Reasons Why Sensex Jumped 505 Points Today(Closing)

Indian share markets continued momentum and ended their session on a strong note today.

Views on news

AJANTA PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 46.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 46.3% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 28.9% (Quarterly Result Update)

Aug 24, 2020 | Updated on Aug 24, 2020

For the quarter ended June 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 7 bn (up 9.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.

More Views on News

Most Popular

Not Infosys or Wipro. India's Next Wealth Creators Could Be Drone Stocks (Profit Hunter)

Nov 25, 2020

India's drones directorate signals the next big defence tech multibaggers.

It's Time to Book Profits (Fast Profits Daily)

Nov 27, 2020

In my first video on Equitymaster, I want to introduce you my proprietary greed and fear index. It's telling us to book some profits in the market.

How the New Margins Will Impact You (Fast Profits Daily)

Nov 25, 2020

The new rules on margins will come into effect from 1st December. Are you ready?

Is this Sector the Best Contrarian Bet Right Now? (Profit Hunter)

Nov 23, 2020

The risk reward ratio in this beaten down sector may have finally turned for the better.

The Price of Dying, the Cost of Living (The Honest Truth)

Nov 20, 2020

Ajit Dayal presents a cost benefit analysis of the various types of response to covid around the world.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Dec 1, 2020 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AJANTA PHARMA

AJANTA PHARMA - TEVA PHARMA COMPARISON

COMPARE AJANTA PHARMA WITH

MARKET STATS